To analyze such mechanisms, murine (CMT167, LLC and KLA) and human (H1792, H2009, A549 and H2030) trametinib resistant (TR) KRAS-mutant LUAD cells were generated as previously described [27] and tumor cells were considered TR when their trametinib IC50 at 72 h became significantly higher than the IC50 of parental cells treated with trametinib [41] (Supplementary Fig. S5A). Here, KRAS is linked to neoplasm.